Refractory Dermatomyositis–Systemic Lupus Erythematosus Overlap Syndrome and Response to Tofacitinib
September 2020
in “
Proceedings - Baylor University. Medical Center
”
New to Tofacitinib? There is a guide in the encyclopedia. Read the guide → Studysummary In this case report, a 39-year-old woman's symptoms from dermatomyositis–systemic lupus erythematosus overlap syndrome improved only after she was treated with tofacitinib.
Our plain-language summary. Not medical advice or a treatment recommendation. Consult a qualified healthcare professional before changing treatment. Full disclaimer
A 39-year-old woman with a dermatomyositis–systemic lupus erythematosus overlap syndrome experienced severe symptoms including muscle weakness, rash, and hair loss, which were refractory to initial treatments. After a 2.5-month hospitalization and various treatments, her symptoms significantly improved with the administration of tofacitinib, a janus kinase inhibitor. This case highlighted the diagnostic challenges of overlap syndromes and demonstrated the efficacy of tofacitinib in reducing symptoms and steroid dependency in such conditions.
